Evogene Ltd.
corporate_fare Company Profile
Evogene Ltd. (NASDAQ:EVGN) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 34 items for EVGN at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Subsidiary Biomica's Cancer Drug Shows Favorable Safety, Clinical Activity in Phase 1 Study
- Evogene Reports 86% Q1 Revenue Plunge, $5.87M Net Loss; Raises Capital via Warrants
- Selling Shareholder Offers 2.45M Shares Amidst Delisting Concerns
- Evogene Reports Worsening Q1 Financials Amidst Strategic Pivot and Nasdaq Delisting Risk
- Evogene's Herbicide Project with Bayer Terminated Due to Failed Target Protein
Financial Snapshot
Insider Transactions
EVGN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.